Your browser doesn't support javascript.
loading
Treatment With Liposomal Amphotericin B for All Confirmed Cases of Human Visceral Leishmaniasis in Brazil: A Budget Impact Analysis.
Silva Ferreira de Carvalho, Isis Polianna; Peixoto, Henry Maia; Sierra Romero, Gustavo Adolfo; Fernandes de Oliveira, Maria Regina.
Afiliação
  • Silva Ferreira de Carvalho IP; Centre for Tropical Medicine, University of Brasilia, Brasilia, Federal District, Brazil. Electronic address: isispolianna@gmail.com.
  • Peixoto HM; Centre for Tropical Medicine, University of Brasilia, Brasilia, Federal District, Brazil; National Institute for Science and Technology for Health Technology Assessment, Porto Alegre, RS, Brazil.
  • Sierra Romero GA; Centre for Tropical Medicine, University of Brasilia, Brasilia, Federal District, Brazil; National Institute for Science and Technology for Health Technology Assessment, Porto Alegre, RS, Brazil.
  • Fernandes de Oliveira MR; Centre for Tropical Medicine, University of Brasilia, Brasilia, Federal District, Brazil; National Institute for Science and Technology for Health Technology Assessment, Porto Alegre, RS, Brazil.
Value Health Reg Issues ; 23: 77-84, 2020 Dec.
Article em En | MEDLINE | ID: mdl-32961526
OBJECTIVES: To estimate the budget impact of the expansion of liposomal amphotericin B use for all confirmed cases of visceral leishmaniasis (VL) in Brazil. Currently, the first-line medicine for VL treatment is meglumine antimoniate. Liposomal amphotericin B is indicated only for patients with a greater risk of severity by the disease. METHODS: The analysis was performed from the perspective of the Brazilian public healthcare system over 3 years, considering the following 2 scenarios: the reference scenario with the current recommendations for VL treatment and the alternative scenario based on the use of liposomal amphotericin B for all patients. A diffusion rate of 60% was used in the first year, 80% in the second year, and 100% in the third year. The epidemiological parameters used in the analysis came from the Notifiable Diseases Information System and from a clinical trial that evaluated the efficacy and safety of medicines for the treatment of VL in the country. The costs were related to the treatment of VL and to hospital and outpatient care. RESULTS: In the reference scenario, the total cost for treatment of the 3453 VL confirmed cases in 2014 was $1 447 611.75. The incremental budget impact with the use of liposomal amphotericin B for all the VL confirmed cases was $299 646.43 in the third year. CONCLUSIONS: The analysis presented will support the decision process for the use and expansion of liposomal amphotericin B for all VL confirmed cases in Brazil.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Orçamentos / Anfotericina B / Análise Custo-Benefício / Leishmaniose Visceral Tipo de estudo: Clinical_trials / Guideline / Health_economic_evaluation / Prognostic_studies Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Value Health Reg Issues Ano de publicação: 2020 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Orçamentos / Anfotericina B / Análise Custo-Benefício / Leishmaniose Visceral Tipo de estudo: Clinical_trials / Guideline / Health_economic_evaluation / Prognostic_studies Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Value Health Reg Issues Ano de publicação: 2020 Tipo de documento: Article País de publicação: Estados Unidos